Gary Purk is the CEO of ChyloCure, a startup specialising in a unique magnesium-infused CBDa compound – a next-generation CBD product which is superior to CBD. He joins the show to talk about the economics of direct-to-consumer models versus traditional distribution channels, focusing particularly on the hurdles of maintaining low customer acquisition costs. 

Gary unpacks the product's health benefits, the substantial cost analysis beyond the production line, and the impact of imminent industry regulation changes. He also reflects on the risks and rewards associated with managing inventory, compliance costs, and marketing in an industry filled with both potential and pitfalls.

Website: https://chylocure.com/ 
Twitter: https://twitter.com/purkgary 
LinkedIn: https://www.linkedin.com/in/garypurk/